Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Syndax Pharmaceuticals Inc | SNDX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 20.79 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 20.79 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 11.215 - 25.34 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 20.79 | USD |
Syndax Pharmaceuticals (SNDX) Options Flow Summary
Syndax Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.77B | 84.97M | - | 0 | -209.36M | -2.46 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Syndax Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNDX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.74 | 21.54 | 20.36 | 20.77 | 814,158 | 0.05 | 0.24% |
| 1 Month | 23.18 | 24.375 | 20.36 | 22.11 | 914,142 | -2.39 | -10.31% |
| 3 Months | 20.59 | 25.34 | 20.085 | 22.66 | 1,101,382 | 0.20 | 0.97% |
| 6 Months | 12.24 | 25.34 | 11.51 | 19.81 | 1,360,194 | 8.55 | 69.85% |
| 1 Year | 21.13 | 25.34 | 11.215 | 18.51 | 1,291,534 | -0.34 | -1.61% |
| 3 Years | 15.32 | 29.86 | 11.215 | 19.36 | 861,730 | 5.47 | 35.70% |
| 5 Years | 6.91 | 29.86 | 5.35 | 18.84 | 692,898 | 13.88 | 200.87% |
Syndax Pharmaceuticals Description
| Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
